

Eric Mcdade

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11938895/publications.pdf>

Version: 2024-02-01

68
papers

8,097
citations

109321

35
h-index

106344

65
g-index

70
all docs

70
docs citations

70
times ranked

9980
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 795-804.	27.0	3,005
2	Symptom onset in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2014, 83, 253-260.	1.1	391
3	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. <i>Lancet Neurology</i> , The, 2018, 17, 241-250.	10.2	383
4	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. <i>Annals of Neurology</i> , 2016, 79, 929-939.	5.3	381
5	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2020, 26, 398-407.	30.7	351
6	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4502-9.	7.1	309
7	Effect of <i>APOE</i> ϵ 4 Status on Intrinsic Network Connectivity in Cognitively Normal Elderly Subjects. <i>Archives of Neurology</i> , 2011, 68, 1131.	4.5	197
8	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. <i>Neurology</i> , 2018, 91, e1295-e1306.	1.1	193
9	Stop Alzheimer's before it starts. <i>Nature</i> , 2017, 547, 153-155.	27.8	189
10	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	30.7	182
11	Developing an international network for Alzheimer's research: the Dominantly Inherited Alzheimer Network. <i>Clinical Investigation</i> , 2012, 2, 975-984.	0.0	180
12	Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: A population-based study. <i>Annals of Neurology</i> , 2012, 71, 49-56.	5.3	179
13	Impaired default network functional connectivity in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2013, 81, 736-744.	1.1	174
14	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1111.	9.0	112
15	Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 985-993.	1.2	112
16	Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). <i>Lancet Neurology</i> , The, 2016, 15, 1317-1325.	10.2	87
17	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	2.4	84
18	Amyloid- β Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S151-S159.	2.6	80

#	ARTICLE	IF	CITATIONS
19	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , 2018, 141, 1486-1500.	7.6	79
20	Cognitive trajectories associated with β^2 -amyloid deposition in the oldest-old without dementia. <i>Neurology</i> , 2013, 80, 1378-1384.	1.1	77
21	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. <i>Lancet Neurology</i> , The, 2022, 21, 329-341.	10.2	72
22	<i>BDNF</i> Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. <i>Brain</i> , 2016, 139, 2766-2777.	7.6	70
23	Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. <i>Brain</i> , 2015, 138, 1036-1045.	7.6	67
24	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. <i>Brain</i> , 2021, 144, 2176-2185.	7.6	66
25	The <i>BDNF</i> Val66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 614-628.	7.9	61
26	Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition. <i>Alzheimer's and Dementia</i> , 2018, 14, 743-750.	0.8	51
27	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1427-1437.	0.8	51
28	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0195838.	2.5	51
29	Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects. <i>NeuroImage: Clinical</i> , 2015, 9, 592-598.	2.7	48
30	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine learning. <i>Alzheimer's and Dementia</i> , 2020, 16, 501-511.	0.8	47
31	Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. <i>Neurology</i> , 2014, 83, 1804-1811.	1.1	46
32	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , 2016, 11, e0152082.	2.5	45
33	The informed road map to prevention of Alzheimer Disease: A call to arms. <i>Molecular Neurodegeneration</i> , 2021, 16, 49.	10.8	43
34	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 1225.	3.3	42
35	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. <i>Alzheimer's and Dementia</i> , 2018, 14, 43-53.	0.8	42
36	Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2014, 83, 710-717.	1.1	41

#	ARTICLE	IF	CITATIONS
37	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2019, 142, 1429-1440.	7.6	36
38	Variant-dependent heterogeneity in amyloid β^2 burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. <i>Lancet Neurology</i> , The, 2022, 21, 140-152.	10.2	34
39	Rates and risk factors for progression to incident dementia vary by age in a population cohort. <i>Neurology</i> , 2015, 84, 72-80.	1.1	33
40	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 142, 104960.	4.4	31
41	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 776-785.	1.3	30
42	Discovery and validation of autosomal dominant Alzheimer's disease mutations. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 67.	6.2	29
43	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2015, 85, 790-798.	1.1	27
44	Seizures as an early symptom of autosomal dominant Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 76, 18-23.	3.1	27
45	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease. <i>NeuroImage</i> , 2022, 256, 119228.	4.2	27
46	Effect of <i>BDNF</i> Val66Met on disease markers in dominantly inherited Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 84, 424-435.	5.3	25
47	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. <i>JAMA Network Open</i> , 2019, 2, e1917126.	5.9	23
48	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. <i>Brain Connectivity</i> , 2021, 11, 239-249.	1.7	18
49	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.1	16
50	Comparing amyloid- β^2 plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. <i>Acta Neuropathologica</i> , 2021, 142, 689-706.	7.7	15
51	Association of <i>BDNF</i> Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 261.	9.0	15
52	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 669-677.	2.4	14
53	Dominantly inherited Alzheimer's disease in Latin America: Genetic heterogeneity and clinical phenotypes. <i>Alzheimer's and Dementia</i> , 2021, 17, 653-664.	0.8	14
54	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). <i>Alzheimer's and Dementia</i> , 2020, 16, 219-228.	0.8	13

#	ARTICLE	IF	CITATIONS
55	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 2687-2698.	0.8	13
56	Modeling autosomal dominant Alzheimer's disease with machine learning. <i>Alzheimer's and Dementia</i> , 2021, 17, 1005-1016.	0.8	12
57	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. <i>Brain Communications</i> , 2020, 2, fcaa102.	3.3	11
58	Relationships between big-five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12038.	2.4	9
59	Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a population-based sample. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 127-130.	2.4	6
60	The pathway to secondary prevention of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12069.	3.7	5
61	Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 845-847.	2.6	4
62	Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1754-1764.	0.8	4
63	Cerebral bleed after shunt for normal pressure hydrocephalus with cerebral amyloid angiopathy. <i>Neurology: Clinical Practice</i> , 2015, 5, 263-266.	1.6	3
64	Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	3
65	Reply to: Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 848-849.	2.6	2
66	Biomarker clustering in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 274-284.	0.8	2
67	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 0, , .	0.8	2
68	Targeting Alzheimer's Disease in the Preclinical Stage. , 2019, 15, 602-603.		0